118 related articles for article (PubMed ID: 36996792)
1. Oncostatin M and Nivolumab Affect the Cytotoxic T-Cell Proportions and the Susceptibility to TRAIL-Induced Death in Non-Leukocyte Cell Subpopulations in Soft Tissue Sarcomas.
Toffanin G; Ozaniak A; Bartolini R; Komarc M; Novysedlak R; Rataj M; Smetanova J; Rosato A; Lischke R; Bartunkova J; Strizova Z
Pharmacology; 2023; 108(3):274-285. PubMed ID: 36996792
[TBL] [Abstract][Full Text] [Related]
2. A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade.
Ozaniak A; Smetanova J; Bartolini R; Rataj M; Capkova L; Hacek J; Fialova M; Krupickova L; Striz I; Lischke R; Bartunkova J; Strizova Z
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3789-3801. PubMed ID: 35986756
[TBL] [Abstract][Full Text] [Related]
3. Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.
Smigiel JM; Parameswaran N; Jackson MW
Mol Cancer Res; 2017 Apr; 15(4):478-488. PubMed ID: 28053127
[TBL] [Abstract][Full Text] [Related]
4. Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect.
Wang ML; Pan CM; Chiou SH; Chen WH; Chang HY; Lee OK; Hsu HS; Wu CW
Cancer Res; 2012 Nov; 72(22):6051-64. PubMed ID: 23139208
[TBL] [Abstract][Full Text] [Related]
5. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
[TBL] [Abstract][Full Text] [Related]
6. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation.
Boniface K; Diveu C; Morel F; Pedretti N; Froger J; Ravon E; Garcia M; Venereau E; Preisser L; Guignouard E; Guillet G; Dagregorio G; Pène J; Moles JP; Yssel H; Chevalier S; Bernard FX; Gascan H; Lecron JC
J Immunol; 2007 Apr; 178(7):4615-22. PubMed ID: 17372020
[TBL] [Abstract][Full Text] [Related]
7. Oncostatin M: Potential Implications for Malignancy and Metabolism.
Stephens JM; Elks CM
Curr Pharm Des; 2017; 23(25):3645-3657. PubMed ID: 28677505
[TBL] [Abstract][Full Text] [Related]
8. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
9. Oncostatin M-Enriched Small Extracellular Vesicles Derived from Mesenchymal Stem Cells Prevent Isoproterenol-Induced Fibrosis and Enhance Angiogenesis.
Tejedor S; Buigues M; González-King H; Silva AM; García NA; Dekker N; Sepúlveda P
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047440
[TBL] [Abstract][Full Text] [Related]
10. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
[TBL] [Abstract][Full Text] [Related]
11. Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts.
Le Goff B; Singbrant S; Tonkin BA; Martin TJ; Romas E; Sims NA; Walsh NC
Cytokine; 2014 Aug; 68(2):101-9. PubMed ID: 24767864
[TBL] [Abstract][Full Text] [Related]
12. STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.
Bryson BL; Junk DJ; Cipriano R; Jackson MW
Cell Cycle; 2017 Feb; 16(4):319-334. PubMed ID: 27892764
[TBL] [Abstract][Full Text] [Related]
13. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M is a growth factor for Ewing sarcoma.
David E; Tirode F; Baud'huin M; Guihard P; Laud K; Delattre O; Heymann MF; Heymann D; Redini F; Blanchard F
Am J Pathol; 2012 Nov; 181(5):1782-95. PubMed ID: 22982441
[TBL] [Abstract][Full Text] [Related]
15. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
[TBL] [Abstract][Full Text] [Related]
16. Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways.
Wang H; Lei L; Hu J; Li Y
Exp Physiol; 2020 Jul; 105(7):1151-1158. PubMed ID: 32359099
[TBL] [Abstract][Full Text] [Related]
17. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
18. The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
Nose Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Yamamoto K; Makino T; Takahashi T; Kawashima A; Haruna M; Hirata M; Ueyama A; Iwahori K; Satoh T; Kurokawa Y; Eguchi H; Doki Y; Wada H
Cancer Immunol Immunother; 2023 Jan; 72(1):169-181. PubMed ID: 35776160
[TBL] [Abstract][Full Text] [Related]
19. Oncostatin M-induced upregulation of SDF-1 improves Bone marrow stromal cell migration in a rat middle cerebral artery occlusion stroke model.
Han J; Feng Z; Xie Y; Li F; Lv B; Hua T; Zhang Z; Sun C; Su D; Ouyang Q; Cai Y; Zou Y; Tang Y; Sun H; Jiang X
Exp Neurol; 2019 Mar; 313():49-59. PubMed ID: 30213507
[TBL] [Abstract][Full Text] [Related]
20. Loss of Oncostatin M Signaling in Adipocytes Induces Insulin Resistance and Adipose Tissue Inflammation in Vivo.
Elks CM; Zhao P; Grant RW; Hang H; Bailey JL; Burk DH; McNulty MA; Mynatt RL; Stephens JM
J Biol Chem; 2016 Aug; 291(33):17066-76. PubMed ID: 27325693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
